In this issue:
BVL in MS
NEPAD in PPMS
MS pregnancy rates and outcomes in the US
Treatment change among MS patients with clinically silent new MRI lesions
Air pollution and MS inflammatory activity
Amiselimod in RRMS
Cladribine vs fingolimod, natalizumab and interferon β for MS
Natalizumab during pregnancy and lactation
Effectiveness of FES for MS
Cladribine induces OCBs disappearance in RRMS
NEDA status over 3 years in a real-world cohort of RRMS
Please login below to download this issue (PDF)